Scarica l'app Stockscreener
4.275
0.58%
-0.025
Dopo l'orario di chiusura:
4.25
-0.025
-0.58%
Precedente Chiudi:
$4.30
Aprire:
$4.41
Volume 24 ore:
396.05K
Relative Volume:
0.32
Capitalizzazione di mercato:
$277.75M
Reddito:
$202.09M
Utile/perdita netta:
$-61.69M
Rapporto P/E:
-3.9583
EPS:
-1.08
Flusso di cassa netto:
$-35.64M
1 W Prestazione:
-3.06%
1M Prestazione:
-25.91%
6M Prestazione:
-33.20%
1 anno Prestazione:
-70.02%
Intervallo 1D:
$4.19
$4.445
Intervallo di 1 settimana:
$4.0913
$4.61
Portata 52W:
$4.0913
$17.12
Evolus Inc Stock (EOLS) Company Profile
Nome
Evolus Inc
Settore
Telefono
(949) 284-4555
Indirizzo
520 NEWPORT CENTER DRIVE, NEWPORT BEACH
Compare EOLS vs TAK, ZTS, HLN, TEVA, UTHR
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
EOLS
Evolus Inc
|
4.285 | 278.73M | 202.09M | -61.69M | -35.64M | -1.08 |
|
TAK
Takeda Pharmaceutical Co Adr
|
18.38 | 57.75B | 29.85B | 776.90M | 4.35B | 0.2408 |
|
ZTS
Zoetis Inc
|
125.63 | 56.70B | 9.40B | 2.65B | 2.24B | 5.935 |
|
HLN
Haleon Plc Adr
|
11.16 | 49.70B | 14.26B | 1.98B | 2.47B | 0.4327 |
|
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
33.92 | 39.96B | 17.41B | 1.43B | 1.00B | 1.2182 |
|
UTHR
United Therapeutics Corp
|
476.07 | 20.49B | 3.13B | 1.27B | 1.12B | 26.39 |
Evolus Inc Stock (EOLS) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-08-06 | Downgrade | Needham | Buy → Hold |
| 2025-04-17 | Iniziato | BTIG Research | Buy |
| 2024-01-29 | Aggiornamento | Barclays | Equal Weight → Overweight |
| 2022-06-23 | Iniziato | Needham | Buy |
| 2022-05-12 | Aggiornamento | Barclays | Underweight → Equal Weight |
| 2022-01-20 | Aggiornamento | Truist | Hold → Buy |
| 2021-05-06 | Aggiornamento | Mizuho | Neutral → Buy |
| 2021-04-08 | Reiterato | H.C. Wainwright | Buy |
| 2021-02-24 | Downgrade | Truist | Buy → Hold |
| 2020-07-07 | Downgrade | Mizuho | Buy → Neutral |
| 2020-02-06 | Ripresa | Mizuho | Buy |
| 2019-11-26 | Iniziato | SVB Leerink | Outperform |
| 2019-09-05 | Ripresa | Mizuho | Buy |
| 2019-06-28 | Iniziato | Wells Fargo | Market Perform |
| 2019-06-11 | Iniziato | Barclays | Underweight |
| 2019-03-20 | Iniziato | SunTrust | Buy |
| 2019-02-14 | Iniziato | H.C. Wainwright | Buy |
| 2019-01-29 | Iniziato | Stifel | Buy |
Mostra tutto
Evolus Inc Borsa (EOLS) Ultime notizie
What Catalysts Are Rewriting The Evolus (EOLS) Story After The Guidance Reset - Yahoo Finance
Mizuho Lowers Price Target on Evolus, Inc. (EOLS) to $15, Maintains Outperform Rating - Insider Monkey
CEO Change: Is Evolus Inc undervalued by DCF analysis2025 Trade Ideas & AI Driven Price Forecasts - baoquankhu1.vn
Aug Patterns: Is Evolus Inc showing insider buyingMarket Trend Report & AI Forecast for Swing Trade Picks - baoquankhu1.vn
Evolus, Inc. (NASDAQ:EOLS) Given Average Rating of "Moderate Buy" by Brokerages - MarketBeat
What is HC Wainwright's Forecast for Evolus FY2026 Earnings? - MarketBeat
HC Wainwright Forecasts Evolus' Q4 Earnings (NASDAQ:EOLS) - MarketBeat
Mizuho lowers Evolus stock price target to $15 on guidance reset - Investing.com Canada
Aug Opening: What hedge funds are buying Evolus IncWatch List & AI Optimized Trade Strategies - baoquankhu1.vn
Volatility Watch: What is the earnings history of Evolus IncPortfolio Update Report & Safe Entry Zone Tips - baoquankhu1.vn
H.C. Wainwright lowers Evolus stock price target to $13 on aesthetics headwinds - Investing.com Canada
HC Wainwright Lowers Evolus (NASDAQ:EOLS) Price Target to $13.00 - MarketBeat
Evolus, Inc. (EOLS) Stock Analysis: Unveiling A Compelling 264.81% Upside Potential - DirectorsTalk Interviews
Botulinum Toxin Market to Grow Strongly Through 2030 | Aesthetic - openPR.com
How A New Price Target Is Shaping The Evolus (EOLS) Story - Yahoo Finance
Evolus (NASDAQ:EOLS) Given New $13.00 Price Target at BTIG Research - MarketBeat
EOLS: BTIG Lowers Price Target While Maintaining Buy Rating | EO - GuruFocus
Understanding Momentum Shifts in (EOLS) - Stock Traders Daily
BTIG lowers Evolus stock price target to $13 on aesthetic market decline - Investing.com Nigeria
Evolus projects robust 2025 growth with upcoming product launches - MSN
Panic Selling: Should you avoid Evolus Inc stock right nowEarnings Performance Report & Capital Efficient Trade Techniques - baoquankhu1.vn
Lacklustre Performance Is Driving Evolus, Inc.'s (NASDAQ:EOLS) 30% Price Drop - 富途牛牛
VIX Spike: Is Evolus Inc undervalued by DCF analysis2025 Market WrapUp & Safe Entry Trade Reports - baoquankhu1.vn
Stifel Analyst Lowers Price Target on Evolus (EOLS) to $17.00 | - GuruFocus
Stifel lowers Evolus stock price target to $17 on tempered growth outlook - Investing.com Australia
Stifel lowers Evolus stock price target to $17 on tempered growth outlook By Investing.com - Investing.com South Africa
Evolus, Inc. (NASDAQ:EOLS) Given Consensus Recommendation of "Moderate Buy" by Analysts - MarketBeat
Avoiding Lag: Real-Time Signals in (EOLS) Movement - Stock Traders Daily
Evolus reports 15% Q4 growth, projects 2026 profitability By Investing.com - Investing.com Nigeria
Evolus sees FY26 revenue $327M-$337M, consensus $351.66M - TipRanks
Evolus sees Q4 revenue $88.6M-$90.6M, consensus $90.91M - TipRanks
Evolus, Inc. (EOLS) Stock Analysis: Unpacking a 222% Potential Upside in the Aesthetic Market - DirectorsTalk Interviews
EOLS: HC Wainwright & Co. Reiterates Buy Rating with $20 Price T - GuruFocus
Evolus' (EOLS) "Buy" Rating Reaffirmed at HC Wainwright - MarketBeat
Evolus (EOLS) Projects Strong Revenue Growth Through 2028 - GuruFocus
EOLS Projects Strong Revenue Growth with Key Product Line - GuruFocus
Evolus (EOLS) Achieves Sixth Year of Double-Digit Growth in 2025 - GuruFocus
EOLS Projects Optimistic Growth with Strategic Market Expansion - GuruFocus
Evolus outlook FY sales USD 327-337 million - marketscreener.com
Evolus reports 15% Q4 growth, projects 2026 profitability - Investing.com
Evolus Announces Preliminary Unaudited Fourth Quarter and Full-Year 2025 Net Revenue - Business Wire
How Evolus Inc. stock valuations compare to rivalsMarket Growth Review & Stock Timing and Entry Methods - Улправда
Does Evolus Inc. stock trade at a discount to peersChart Signals & Reliable Breakout Forecasts - Улправда
Why Evolus Inc. stock is favored by top institutions2025 Performance Recap & Expert Curated Trade Setup Alerts - Улправда
Can Evolus Inc. stock deliver strong Q4 earningsSwing Trading Ideas & Small Budget Portfolio Growth - Улправда
Insider Sellers Might Regret Selling Evolus Shares at a Lower Price Than Current Market Value - simplywall.st
Mizuho cuts Evolus (EOLS) estimates for Jeuveau/Evolysse on waning consumer sentiment and inflationary pressure on elective aesthetics - MSN
Will Evolus Inc. (EVL) stock benefit from sector leadershipRisk Mitigation Techniques & Low Entry Cost Investments - ulpravda.ru
Analysts Offer Insights on Healthcare Companies: Arrowhead Pharmaceuticals (ARWR) and Evolus (EOLS) - The Globe and Mail
Evolus Inc Azioni (EOLS) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
0.53%
10.56%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):